KAPA (Kairos Pharma Ltd.) stock: $1.73, $5.9M market cap, $2.6M cash, $3.3M EV, $48.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
ENV105
Phase 2 · Active Modality: monoclonal antibody (anti-endoglin/CD105)
Aliases carotuximab, TRC105
Target endoglin (CD105)
Partnerships Exclusive licenses from Cedars-Sinai Medical Center (endoglin antagonism patents) and license to TRC105/CD105 technologies from Tracon Pharmaceuticals (transferred to Kairos Oct 2025). Phase 2 prostate trial supported by a $3.2M NIH grant to Cedars-Sinai (Dr. Bhowmick) for mechanism-of-action and companion biomarker corollary studies.
Indications- Metastatic castration-resistant prostate cancer (with apalutamide) (Phase 2)
- Lung cancer (with Tagrisso/osimertinib, EGFR antagonist resistance) (Phase 1)
Status note Anti-endoglin (CD105) antibody addressing resistance mechanisms: androgen therapy resistance in prostate cancer and EGFR antagonist resistance in lung cancer. Randomized Phase 2 in prostate cancer with apalutamide at Cedars-Sinai, University of Utah and City of Hope; Phase 1 in lung cancer with Tagrisso (AstraZeneca) at Cedars-Sinai. A three-gene companion biomarker panel is being verified in the Phase 2 trial for future patient selection.
ENV205
Stage not disclosed · Active Modality: biologic
Target circulating mitochondrial DNA
Indications- Chemotherapy-resistant prostate cancer (Stage not disclosed)
Status note Biologic that depletes elevated circulating mitochondrial DNA associated with chemotherapy resistance, cardiac toxicity and systemic inflammatory side effects; designed to restore chemotherapy sensitivity in resistant prostate cancers. Not approved; early-stage development.
KROS101
Stage not disclosed · Active Modality: small molecule
Target GITR ligand
Indications- Cancer (Stage not disclosed)
Status note Small molecule that induces trimerization of the GITR ligand. Development stage not disclosed.
KROS201
Stage not disclosed · Active Modality: cell therapy (dendritic cell-stimulated T cells)
Indications- Glioblastoma (Stage not disclosed)
Status note T cells stimulated by dendritic cells in vitro to target cancer stem cells; initial focus glioblastoma. Development stage not disclosed.
KROS102
Stage not disclosed · Active Modality: small molecule
Target GITR ligand
Indications- Cancer (Stage not disclosed)
Status note GITR ligand antagonist designed to increase inhibitory Treg functions while hampering T effector cell function. Development stage not disclosed.
KROS301
Stage not disclosed · Active Modality: small molecule
Target RelA (NF-kB)
Indications- Cancer (Stage not disclosed)
Status note Tumor-targeting small molecule and checkpoint inhibitor with two mechanisms via blocking intranuclear localization of RelA (NF-kB pathway); reverses immune suppression at the tumor site. Development stage not disclosed.
KROS401
Stage not disclosed · Active Modality: peptide
Target IL-4 / IL-13
Indications- Cancer (Stage not disclosed)
Status note Tumor microenvironment immune modulator; cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor-associated macrophage inhibition. Development stage not disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.